OBJECTIVE

This study aimed to determine if selenium supplementation for a period of six months can decrease signs and prevent worsening of mild Graves’ ophthalmopathy among Filipino patients.

METHODS

We conducted an open-label, assessor-masked, randomized controlled trial involving adult patients diagnosed with mild Graves’ ophthalmopathy. Participants were divided into two groups: one group received standard care (eye drops) alone (control group), while the other group received an additional 200 mcg/day oral selenium supplementation alongside standard care. Inclusion criteria encompassed adult patients with Graves’ hyperthyroidism presenting at least one sign of mild ophthalmopathy and a disease duration of less than 18 months. Statistical analyses were performed using independent sample t-test, Mann-Whitney U test and Fisher’s Exact/Chi-square test to compare means, ranks and frequencies between the two intervention groups. Paired sample t-test, Wilcoxon signed rank test and McNemar test were employed to assess changes from baseline to the third and sixth month observations.

RESULTS

A significant difference in clinical activity score (CAS) was observed between the selenium supplementation group and the control group. Initially, 14 eyes (33.33%) in the selenium group exhibited a CAS score of 0, which increased to 27 eyes (64.29%) at the third month of treatment and slightly decreased to 26 eyes (61.9%) at the sixth month. Conversely, the control group had 11 eyes with a CAS score of 0 at baseline, which increased to 16 eyes (38.1%) at three months and decreased to 14 eyes (33.33%) at the sixth month. The improvement in CAS was significantly associated with reductions in caruncle and plica swelling (p = 0.040). Further analysis revealed a statistically significant difference in CAS between the treatment and control groups (p = 0.017) at the sixth month mark.

CONCLUSION

Selenium supplementation provided significant benefit in reducing the signs and preventing deterioration of mild Graves’ ophthalmopathy, as indicated by improved CAS scores. Future research exploring baseline and end of treatment selenium concentrations in the Philippines is recommended to further substantiate these findings.

Human ; Female ; Randomized Controlled Trial ; Tertiary Care Centers

INTRODUCTION

Patients with diabetes are at higher risk of developing severe COVID-19 infection with a two-fold increased risk of mortality. This study described the risk factors affecting clinical outcomes of confirmed COVID-19 patients with diabetes mellitus at the University of Santo Tomas Hospital, Manila, Philippines.

METHOD

This retrospective study included 204 patients with COVID-19 (34 with known type 2 diabetes and 2 with new-onset diabetes) from March to October 2020. Clinical characteristics and laboratory parameters were collected and analyzed in subjects with diabetes. A univariate logistic regression was used to calculate the odds ratios and 95% confidence interval (CI) for the patient’s risk factors associated with mortality or poor prognosis.

RESULTS

Moderate COVID-19 infection occurred in 52.8% of type 2 diabetes mellitus (T2DM) patients and critical COVID-19 infection in 27.8%. All patients with critical COVID-19 infection presented with acute respiratory distress syndrome, half had concomitant septic shock and respiratory failure was observed in 27.8%. The average length of hospital stay was approximately 17.5 days. T2DM patients with established atherosclerotic cardiovascular disease (ASCVD) are 5.1 times (95% CI 1.2 to 21.4) more likely to develop severe or critical COVID-19 infection, and more likely to stay in the hospital for more than 14 days. HbA1c >8.5% is a potential risk (OR = 3.7, 0.6 to 21.6) for severe to critical disease. T2DM patients with concomitant coronary artery disease are 7.6 times (95% CI 1.3 to 43.4) more likely to stay longer (more than 14 days) as compared to those without existing coronary artery disease. Prior statin use was a significant risk factor for ICU admission (p-value 0.0341). Other potential risk factors affecting clinical outcomes are obesity (OR 3, 0.4 to 22.7), prior use of thiazolidinedione (OR 7.8, 0.5 to 126.7) or sodium-glucose transporter 2 (SGLT2) inhibitors (OR 7.5, 0.4 to 145) and prior use of anti-thrombotic (OR 4.6, 0.4 to 56.8). The recovery rate of T2DM patients hospitalized for COVID-19 infection was 86.1%.

CONCLUSION

Patients with T2DM are more vulnerable to COVID-19 infection. The presence of established ASCVD increases the likelihood of severe COVID-19 disease as well as longer length of hospital stay for more than 14 days. Early recognition and prompt treatment led to a favorable recovery rate.

Human ; Covid-19 ; Diabetes Mellitus, Type 2

The presence of autoantibodies is a common link between autoimmune hypothyroidism (AH) and Systemic Lupus Erythematosus (SLE). The coexistence of AH (Hashimoto’s Thyroiditis) and SLE is common; however, massive pericardial effusion (PEEF) with signs of tamponade is extremely rare and only a few cases have been reported in literature. We present a case of a 54-year-old female who came in with progressive dyspnea who was found out to have massive PEEF from overt AH and concurrent SLE, which was successfully managed medically. This gave us valuable insight that massive pericardial effusion occurring in overt hypothyroidism may be secondarily caused by other co-existing disease entities such as SLE. The importance of the correct diagnosis cannot be overemphasized, as this largely contributed to the successful management of this case.
Pericardial Effusion ; Cardiac Tamponade ; Lupus Erythematosus, Systemic